Big Pharma continues to throw ballast out of the balloon in the hopes of staying aloft. The latest victim of declining fortunes in the industry is Merck (MRK), which seems to have had every drug which it submitted to the FDA this year turned down.

Merck’s cholesterol medicine Cordaptive got the thumbs down last week. Researchers are also questioning the value of its Vytorin product, another cholesterol treatment which does not seem to work.

According to The Wall Street Journal, Merck will cut 1,200 sales jobs.

There are more to come. The problems Merck has replacing drugs which are coming off-patent are getting deeper and deeper.

Douglas A. McIntyre

Smart Investors Are Quietly Loading Up on These “Dividend Legends”

If you want your portfolio to pay you cash like clockwork, it’s time to stop blindly following conventional wisdom like relying on Dividend Aristocrats.

There’s a better option, and we want to show you. We’re offering a brand-new report on 2 stocks we believe offer the rare combination of a high dividend yield and significant stock appreciation upside.

If you’re tired of feeling one step behind in this market, this free report is a must-read for you.

Thanks! We will redirect you shortly to the free report!

By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.